NCT03796637View on ClinicalTrials.gov

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren

PHASE2CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

June 3, 2019

Study Completion Date

June 3, 2019

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

Ataluren

Ataluren will be administered as per the dose and schedule specified in the arm.

Trial Locations (1)

90025

University of California, Los Angeles (UCLA), Los Angeles

Sponsors

Lead Sponsor

PTC Therapeutics

All Listed Sponsors

lead

PTC Therapeutics

INDUSTRY

NCT03796637 - A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren | Biotech Hunter | Biotech Hunter